Hematologic Inflammatory Markers and Inflammation-Related Hepatokines in Pediatric Obesity

Authors: Mustafa M. Donma, Orkide Donma

Abstract:

Obesity in children particularly draws attention, because it may threaten the individual’s future life due to many chronic diseases it may lead to. Most of these diseases including obesity itself altogether are related to inflammation. For this reason, inflammation-related parameters gain importance. Within this context, complete blood cell counts, ratios or indices derived from these counts have recently found some platform to be used as inflammatory markers. So far, mostly adipokines were investigated within the field of obesity. Metabolic inflammation is closely associated with cellular dysfunction. In this study, hematologic inflammatory markers and cytokines produced predominantly by the liver (fibroblast growth factor-21 (FGF-21) and fetuin A) were investigated in pediatric obesity. Two groups were constituted from 76 obese children based on World Health Organization criteria. Group 1 was composed of children, whose age- and sex-adjusted body mass index (BMI) percentiles were between 95 and 99. Group 2 consists of children, who are above 99th percentile. The first and the latter groups were defined as obese (OB) and morbid obese (MO). Anthropometric measurements of the children were performed. Informed consent forms and the approval of the institutional ethics committee were obtained. Blood cell counts and ratios were determined by automated hematology analyzer. The related ratios and indexes were calculated. Statistical evaluation of the data was performed by SPSS program. There was no statistically significant difference in terms of neutrophil-to lymphocyte ratio, monocyte-to-high density lipoprotein cholesterol ratio and platelet-to-lymphocyte ratio between the groups. Mean platelet volume and platelet distribution width values were decreased (p < 0.05), total platelet count, red cell distribution width (RDW) and systemic immune inflammation index values were increased (p < 0.01) in MO group. Both hepatokines were increased in the same group, however increases were not statistically significant. In this group, also a strong correlation was calculated between FGF-21 and RDW when controlled by age, hematocrit, iron and ferritin (r = 0.425; p < 0.01). In conclusion, the association between RDW, a hematologic inflammatory marker, and FGF-21, an inflammation-related hepatokine, found in MO group is an important finding discriminating between OB and MO children. This association is even more powerful when controlled by age and iron-related parameters.

Keywords: Childhood obesity, fetuin A, fibroblast growth factor-21, hematologic markers, red cell distribution width.

References:

[1] S. Xu and Y. Xue, “Pediatric obesity: Causes, symptoms, prevention and treatment,” Exp. Ther. Med., vol. 11, pp. 15-20, Jan. 2016.
[2] C. G. Magnussen, J. Koskinen, W. Chen, R. Thomson, M. D. Schmidt, S. R. Srinivasan, M. Kivimäki, N. Mattsson, M. Kähönen, T. Laitinen, L. Taittonen, T. Rönnemaa, J. S. Viikari, G. S. Berenson, M. Juonala, and O. T. Raitakari, “Pediatric metabolic syndrome predicts adulthood metabolic syndrome, subclinical atherosclerosis, and type 2 diabetes mellitus but is no better than body mass index alone: the Bogalusa Heart Study and the Cardiovascular Risk in Young Finns Study,” Circulation, vol. 122, no.16, pp. 1604-1611, Oct. 2010.
[3] M. M. Donma, O. B. Ekmekci, H. Ekmekci, and O. Donma, “Evaluation of the markers affecting obesity in children,” Med One, vol. 2, no. e180004, Apr. 2018.
[4] M. M. Donma, S. D. Erselcan, A. Yilmaz, S. Guzel and O. Donma, “The evaluation of new generation inflammatory markers in children with morbid obesity and metabolic syndrome,” Nam. Kem. Med. J., vol. 8, no. 3, pp.479-488, Dec. 2020.
[5] O. Donma, and M. M. Donma, “The potential involvement of platelet indices in insulin resistance in morbid obese children,” Int. J. Med. Health Sci., vol.14, no.3, pp. 85-88, Feb. 2020.
[6] M. M. Donma, and O. Donma, “The evaluation of complete blood cell count-based inflammatory markers in pediatric obesity and metabolic syndrome,” Int. J. Med. Health Sci., vol.14, no.3, pp. 89-92, Feb. 2020.
[7] S. T. McSorley, A. Tham, C. W. Steele, R. D. Dolan, C. S. Roxburgh, P. G. Horgan, and D. C. McMillan, “Quantitative data on red cell measures of iron status and their relation to the magnitude of the systemic inflammatory response and survival in patients with colorectal cancer,” Eur. J. Surg. Oncol., vol. 45, no. 7, pp. 1205-1211, Jul 2019.
[8] S. Thavaraputta, J. A. Dennis, S. Ball, P. Laoveeravat, and K. Nugent, “Relation of hematologic inflammatory markers and obesity in otherwise healthy participants in the National Health and Nutrition Examination Survey, 2011-2016, ” Proc. (Bayl. Univ. Med. Cent.), vol. 34, no. 1, pp. 17-21, 2021.
[9] M. M. Donma and O. Donma, “Evaluation of systemic immune-inflammation index in obese children,” Int. J. Med. Health Sci., vol.12, no.9, pp. 362-365, May 2018.
[10] P. Dettori, P. Paliogiannis, R. M. Pascale, A. Zinellu, A. A. Mangoni, and G. Pintus, “Blood cell count indexes of systemic inflammation in carotid artery disease: current evidence and future perspectives,” Curr. Pharm. Des., Dec. 2020.
[11] B. Yousefi, S. Sanaie, A. A. Ghamari, H. Soleimanpour, A. Karimian, and A. Mahmoodpoor, “Red cell distribution width as a novel prognostic marker in multiple clinical studies,” Indian J. Crit. Care Med., vol. 24, no. 1, pp. 49-54, Jan. 2020.
[12] A. C. Valenti, M. Vitolo, J. F. Imberti, V. L. Malavasi, and G. Boriani. “Red cell distribution width: a routinely available biomarker with important clinical implications in patients with atrial fibrillation,” Curr. Pharm. Des., Feb. 2021.
[13] R. Targoński, J. Sadowski, M. Starek-Stelmaszczyk, R. Targoński, and A. Rynkiewicz, “Prognostic significance of red cell distribution width and its relation to increased pulmonary pressure and inflammation in acute heart failure,” Cardiol. J., vol.27, no.4, pp.394-403, 2020.
[14] G. Zurauskaite, M. Meier, A. Voegeli, D. Koch, S. Haubitz, A. Kutz, L. Bernasconi, A. Huber, M. Bargetzi, B. Mueller, and P. Schuetz, “Biological pathways underlying the association of red cell distribution width and adverse clinical outcome: Results of a prospective cohort study,” PLoS One., vol. 13, no. 1, no. e0191280, Jan. 2018.
[15] O. Donma, M. M. Donma, B. Nalbantoglu, B. Topcu, F. Tulubas, M. Aydin, T. Gokkus, and A. Gurel, “The importance of erythrocyte parameters in obese children,” Int. J. Med. Health Sci., vol.9, no.5, pp. 361-364, May 2015.
[16] P. Šimják, A. Cinkajzlová, K. Anderlová, J. Kloučková, H. Kratochvílová, Z. Lacinová, P. Kaválková, H. Krejčí, M. Mráz, A. Pařízek, M. Kršek, and M. Haluzík, “Changes in plasma concentrations and mRNA expression of hepatokines fetuin A, fetuin B and FGF21 in physiological pregnancy and gestational diabetes mellitus,” Physiol. Res., vol. 67, no. S3, pp.S531-S542, Nov. 2018.
[17] M. Esfahani, M. Baranchi, and M. T. Goodarzi, “The implication of hepatokines in metabolic syndrome,” Diabetes Metab. Syndr., vol. 13, no. 4, pp. 2477-2480, Jul-Aug. 2019.
[18] T. Reinehr, and C. L. Roth, “Inflammation markers in type 2 diabetes and the metabolic syndrome in the pediatric population,” Curr. Diab. Rep., vol. 18, no. 12, pp. 131-135, Oct. 2018.
[19] T. Reinehr, B. Karges, T. Meissner, S. Wiegand, B. Stoffel-Wagner, R. W. Holl, and J. Woelfle, “Inflammatory markers in obese adolescents with type 2 diabetes and their relationship to hepatokines and adipokines,” J. Pediatr., vol.173, pp. 131-135, Jun. 2016.
[20] S. A Willis, J. A Sargeant, T. Yates, T. Takamura, H. Takayama, V. Gupta, E. Brittain, J. Crawford, S. A. Parry, A. E. Thackray, V. Varela-Mato, D. J. Stensel, R. M. Woods, C. J. Hulston, G. P. Aithal, and J. A. King, “Acute hyperenergetic, high-fat feeding increases circulating FGF21, LECT2, and fetuin-A in healthy men,” J. Nutr., vol. 150, no. 5, pp. 1076-1085, May 2020.
[21] D. Y. Seo, S. H. Park, J. Marquez, H. B. Kwak, T. N. Kim, J. H. Bae, J. H. Koh, and J. Han, “Hepatokines as a molecular transducer of exercise,” J. Clin. Med., vol. 10, no. 3, pp. 385, Jan. 2021.
[22] Y. Badakhshi, and T. Jin, “Current understanding and controversies on the clinical implications of fibroblast growth factor 21,” Crit. Rev. Clin. Lab. Sci., pp. 1-30, Dec. 2020.
[23] L. Geng , K. S. L. Lam, and A. Xu, “The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic,” Nat. Rev. Endocrinol., vol. 16, no. 11, pp. 654-667, Nov. 2020.
[24] P. Jirak, L. Stechemesser, E. Moré, M. Franzen, A. Topf, M. Mirna, V. Paar, R. Pistulli, D. Kretzschmar, B. Wernly, U. C. Hoppe, M. Lichtenauer, and H. Salmhofer, “Clinical implications of fetuin-A,” Adv. Clin. Chem., vol. 89, pp. 79-130, 2019.
[25] N. Akcan, M. Obaid, J. Salem, and Bundak R, “Evidence in obese children: contribution of tri-ponderal mass index or body mass index to dyslipidemia, obesity- inflammation, and insulin sensitivity,” J. Pediatr. Endocrinol. Metab., vol. 33, no. 2, pp. 223-231, Feb. 2020.
[26] T. Reinehr, “Inflammatory markers in children and adolescents with type 2 diabetes mellitus,” Clin. Chim. Acta., vol. 496, pp. 100-107, Sep. 2019.
[27] D. Pal, S. Dasgupta, R. Kundu, S. Maitra, G. Das, S. Mukhopadhyay, S. Ray, S. S. Majumdar, and S. Bhattacharya, “Fetuin a acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance,” Nat. Med., vol. 18, no. 8, pp.1279–1285, Aug. 2012.
[28] P. Arnaud P, and L. Kalabay, “Alpha2-HS-glycoprotein: a protein in search of a function,” Diabetes Metab. Res. Rev., vol. 18, no. 4, pp. 311–314, 2002.
[29] K. N. Robinson, B. Rowitz, U. J. Oliphant, S. M. Donovan, and M. Teran-Garcia, “Larger omental adipocytes correlate with greater Fetuin-A reduction following sleeve gastrectomy,” BMC Obes., vol.6, no.15, May 2019.
[30] M. Yen, O. Donma, F. Yildizfer, O Ekmekci, Z. A. K. Kul, A. E. Imal, Z. Keser, E. Cagil, M. Mengi, H. Ekmekci, S. Sahmay, and M. Donma, “Association of fetuin A, adiponectin, interleukin 10 and total antioxidant capacity with IVF outcomes,” Iran. J. Reprod. Med., vol. 12, no. 11, pp. 747-754, Nov. 2014.
[31] X. Shi, Y. Ohta, X. Liu, J. Shang, R. Morihara, Y. Nakano, T. Feng, Y. Huang, K. Sato, M. Takemoto, N. Hishikawa, T. Yamashita, and K. Abe, “Acute anti-inflammatory markers ITIH4 and AHSG in mice brain of a novel Alzheimer's disease model,” J. Alzheimers Dis., vol. 68, no. 4, pp.1667-1675, 2019.
[32] World Health Organization (WHO). The WHO Child Growth Standards. Available at: http://www.who.int/childgrowth/en/ Accessed on June 10, 2016.
[33] N. Li, H. Zhou, and Q. Tang, “Red blood cell distribution width: a novel predictive indicator for cardiovascular and cerebrovascular diseases,” Dis Markers., vol. 2017, no. 7089493, 2017.
[34] R. Farah, and R. Khamisy-Farah, “Significance of MPV, RDW with the presence and severity of metabolic syndrome,” Exp. Clin. Endocrinol. Diabetes., vol. 123, pp. 567–570, 2015.
[35] S. Wei, W. Zhang, C. Wang, Y. Cao, and L. Li, “Increased hepcidin expression in adipose tissue as a primary cause of obesity-related inhibition of iron absorption,” J. Biol. Regul. Homeost. Agents,, vol. 33, no. 4, pp. 1135-1141, Jul-Aug. 2019.
[36] S. Chen, X. Zhao, L. Ran, J. Wan, X. Wang, Y. Qin, F. Shu, Y. Gao, L. Yuan, Q. Zhang, and M. Mi, “Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial,” Dig. Liver Dis., vol.47, no.3, pp. 226-232, Mar. 2015.
[37] S. S. Wang, Q. Gu, N. Liu, J. Li, and X. Liu, “Aerobic exercise attenuates ectopic renal sinus adipose tissue accumulation-related renal hypoxia injury in obese mice,” Life Sci., no. 119106, Jan. 2021.
[38] M. M. Donma, O. B. Ekmekci, H. Ekmekci, and O. Donma, “Evaluation of the markers affecting obesity in children,” Med One, vol. 2, no. e180004, Apr. 2018.
[39] M. M. Donma, S. D. Erselcan, A. Yilmaz, S. Guzel and O. Donma, “The evaluation of new generation inflammatory markers in children with morbid obesity and metabolic syndrome,” Nam. Kem. Med. J., vol. 8, no. 3, pp.479-488, Dec. 2020.
[40] L. J. Hanks, O. M. Gutiérrez, M. M. Bamman, A. Ashraf, K. L. McCormick, K. Casazza, “Circulating levels of fibroblast growth factor-21 increase with age independently of body composition indices among healthy individuals,” J. Clin. Transl. Endocrinol., Vol. 2, no. 2, pp. 77-82, June 2015.
[41] J. J. Hoffmann, K. C. Nabbe, N. M. van den Broek, “Effect of age and gender on reference intervals of red blood cell distribution width (RDW) and mean red cell volume (MCV),” Clin. Chem. Lab. Med., vol. 53, no. 12, pp. 2015-2019, Nov. 2015.